INDICATORS OF LIFE QUALITY IN PATIENTS WITH INFLAMMATORY DISEASES OF THE SMALL INTESTINAL BACTERIAL OVERGROWTH SYNDROME (ON THE DATA OF THE NOVOSIBIRSK REGISTER)

Abstract

Patients with inflammatory bowel disease (IBD) are characterized by chronic recurrent course, frequent attacks, the presence of extraintestinal manifestations and the occurrence of complications, which leads to a decrease in the quality of life. One of the concomitant conditions in patients with IBD is the small intestinal bacterial overgrowth syndrome (SIBO), which has common clinical manifestations. There is practically no research on the effect of concomitant SIBO in patients with IBD on the quality of life (QOL). Therefore, the study of QOL in patients with IBD with SIBO is an important task for optimizing treatment. Purpose: to study the quality of life in patients with IBD, depending on the presence of SIBO. Material and methods of the study: patients from the registry of inflammatory bowel diseases in Novosibirsk who underwent a hydrogen respiratory test (HBT) on the device «Gastro+». The QOL indicators were determined using the Russian version of the SF-36 and IBDQ questionnaire. Results: in 152 patients with IBD, in whom HBT was carried out, the prevalence of SIBO was 48.0 % (with ulcerative colitis - 45.7 %, with Crohn’s disease - 50.7 %). In the scales of the SF-36 and IBDQ questionnaire significant decrease in QOL values was revealed in patients with IBD with positive results of HBT in comparison with patients with negative results of HBT. After a 2-week course of rifaximin intake, values increased in almost all scales of the SF-36 and IBDQ questionnaires. Conclusion: The obtained data confirm the necessity of correction of SIBO as an independent clinical task that significantly affects QOL of patients with IBD.